276 related articles for article (PubMed ID: 22433611)
61. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin.
Johnsson KM; Ptaszynska A; Schmitz B; Sugg J; Parikh SJ; List JF
J Diabetes Complications; 2013; 27(5):479-84. PubMed ID: 23806570
[TBL] [Abstract][Full Text] [Related]
62. Sodium-Glucose Cotransporter Inhibitors for the Treatment of Type 1 Diabetes Mellitus.
Li N; Chen R; Liu K
Clin Drug Investig; 2020 Nov; 40(11):991-1000. PubMed ID: 32725362
[TBL] [Abstract][Full Text] [Related]
63. Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes.
Jabbour SA; Goldstein BJ
Int J Clin Pract; 2008 Aug; 62(8):1279-84. PubMed ID: 18705823
[TBL] [Abstract][Full Text] [Related]
64. Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus.
Kasichayanula S; Chang M; Hasegawa M; Liu X; Yamahira N; LaCreta FP; Imai Y; Boulton DW
Diabetes Obes Metab; 2011 Apr; 13(4):357-65. PubMed ID: 21226818
[TBL] [Abstract][Full Text] [Related]
65. Development of the sodium-glucose co-transporter 2 inhibitor dapagliflozin for the treatment of patients with type 2 diabetes mellitus.
Gerich JE; Bastien A
Expert Rev Clin Pharmacol; 2011 Nov; 4(6):669-83. PubMed ID: 22111852
[TBL] [Abstract][Full Text] [Related]
66. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
Meng W; Ellsworth BA; Nirschl AA; McCann PJ; Patel M; Girotra RN; Wu G; Sher PM; Morrison EP; Biller SA; Zahler R; Deshpande PP; Pullockaran A; Hagan DL; Morgan N; Taylor JR; Obermeier MT; Humphreys WG; Khanna A; Discenza L; Robertson JG; Wang A; Han S; Wetterau JR; Janovitz EB; Flint OP; Whaley JM; Washburn WN
J Med Chem; 2008 Mar; 51(5):1145-9. PubMed ID: 18260618
[TBL] [Abstract][Full Text] [Related]
67. [Dapagliflozin. Lowering blood glucose levels by increasing glucosuria].
Hinneburg I
Med Monatsschr Pharm; 2013 Apr; 36(4):128-32. PubMed ID: 23654152
[TBL] [Abstract][Full Text] [Related]
68. Dapagliflozin for the treatment of type 2 diabetes: a review of the literature.
Saeed MA; Narendran P
Drug Des Devel Ther; 2014; 8():2493-505. PubMed ID: 25525338
[TBL] [Abstract][Full Text] [Related]
69. Dapagliflozin: where does it fit in the treatment of type 2 diabetes?
Woo VC
Expert Opin Pharmacother; 2009 Oct; 10(15):2527-35. PubMed ID: 19735212
[TBL] [Abstract][Full Text] [Related]
70. Dapagliflozin: an emerging treatment option in type 2 diabetes.
Kipnes M
Expert Opin Investig Drugs; 2009 Mar; 18(3):327-34. PubMed ID: 19243283
[TBL] [Abstract][Full Text] [Related]
71. Pharmacokinetics and pharmacodynamics of dapagliflozin in children and adolescents with type 2 diabetes mellitus.
Tirucherai GS; LaCreta F; Ismat FA; Tang W; Boulton DW
Diabetes Obes Metab; 2016 Jul; 18(7):678-84. PubMed ID: 27291448
[TBL] [Abstract][Full Text] [Related]
72. Nonclinical toxicology assessments support the chronic safety of dapagliflozin, a first-in-class sodium-glucose cotransporter 2 inhibitor.
Tirmenstein M; Dorr TE; Janovitz EB; Hagan D; Abell LM; Onorato JM; Whaley JM; Graziano MJ; Reilly TP
Int J Toxicol; 2013; 32(5):336-50. PubMed ID: 24097127
[TBL] [Abstract][Full Text] [Related]
73. [Dapagliflozin, a novel oral antidiabetic with an uncertain future].
Escudero Vilaplana B; Almodóvar Carretón MJ; Herrero Hernández S
Farm Hosp; 2014 Nov; 38(6):468-74. PubMed ID: 25542657
[TBL] [Abstract][Full Text] [Related]
74. Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study.
Kasichayanula S; Liu X; Zhang W; Pfister M; LaCreta FP; Boulton DW
Clin Ther; 2011 Nov; 33(11):1798-808. PubMed ID: 22030444
[TBL] [Abstract][Full Text] [Related]
75. Efficacy of Mitiglinide Combined with Dapagliflozin in Streptozotocin-nicotinamide-induced Type 2 Diabetic Rats and in Zucker Fatty Rats.
Akahane K; Inoue T; Yokoyama A; Yaguchi A; Ojima K; Kiguchi S; Maruyama K; Kobayashi M; Mori Y
Drug Res (Stuttg); 2015 Aug; 65(8):416-21. PubMed ID: 25188606
[TBL] [Abstract][Full Text] [Related]
76. Design of SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: A History Driven by Biology to Chemistry.
Cai W; Jiang L; Xie Y; Liu Y; Liu W; Zhao G
Med Chem; 2015; 11(4):317-28. PubMed ID: 25557661
[TBL] [Abstract][Full Text] [Related]
77. Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin.
Kasichayanula S; Liu X; Griffen SC; Lacreta FP; Boulton DW
Diabetes Obes Metab; 2013 Mar; 15(3):280-3. PubMed ID: 23061428
[TBL] [Abstract][Full Text] [Related]
78. The role of the kidney in hyperglycemia: a new therapeutic target in type 2 diabetes mellitus.
Hinnen D
J Cardiovasc Nurs; 2013; 28(2):157-65. PubMed ID: 22343215
[TBL] [Abstract][Full Text] [Related]
79. A model-based approach to investigating the relationship between glucose-insulin dynamics and dapagliflozin treatment effect in patients with type 2 diabetes.
Shah M; Stolbov L; Yakovleva T; Tang W; Sokolov V; Penland RC; Boulton D; Parkinson J
Diabetes Obes Metab; 2021 Apr; 23(4):991-1000. PubMed ID: 33368935
[TBL] [Abstract][Full Text] [Related]
80. Molecule of the month. Dapagliflozin.
Drug News Perspect; 2007 Dec; 20(10):645. PubMed ID: 18301798
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
